Bees make wax (lipid) from honey (carbohydrate). Pigs fatten on a grain diet. Indeed, all organisms, from bacteria to mammals, have the enzymes of de novo lipogenesis. The physiologic function of de novo lipogenesis has therefore seemed obvious to biochemists: the de novo lipogenesis pathway links carbohydrates and fats, the 2 most important forms of chemical energy for most organisms.
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Because storage of energy as lipid is much more efficient than storage as carbohydrate, the presumption has been that animals use de novo lipogenesis as a metabolic safety valve for storage of carbohydrate energy present in excess of carbohydrate oxidative needs (ie, carbohydrate energy surplus). On the basis of this presumed role, inhibitors of de novo lipogenesis [such as (-) hydroxycitrate, an inhibitor of ATP citrate (pro-S)-lyase] have received attention as potential therapeutic agents for obesity and hyperlipidemia.
Most experimental data in humans, however, contradict this view of the function of de novo lipogenesis. Initial studies in which indirect calorimetry was used showed little or no net de novo lipogenesis after short-term carbohydrate overfeeding (1) . Subsequent isotopic studies confirmed the absence of quantitatively significant flux through hepatic de novo lipogenesis under most conditions of carbohydrate energy surplus (2, 3) .
In this issue of the Journal, McDevitt et al (4) contribute useful data relevant to this topic. In a well-designed study, these investigators combined whole-body room indirect calorimetry (to measure net fuel oxidation and de novo lipogenesis) with isotopic measurement of hepatic de novo lipogenesis (by isotope incorporation from deuterated water into triacylglycerol of circulating VLDL). McDevitt et al report that hepatic de novo lipogenesis was stimulated by 4 d of surplus carbohydrate energy in women, that this stimulation was not significantly different when the surplus carbohydrate was in the form of glucose or sucrose, and that the de novo lipogenesis values reached were similar for lean and obese women. Additionally, McDevitt et al report that, in all settings, the total de novo lipogenesis flux represented a small fraction of both the surplus carbohydrate energy ingested and the total fat stored in the body. The authors calculated that between 3 and 8 g fat/d was produced through de novo lipogenesis compared with 360-390 g carbohydrate ingested/d and 60-75 g body fat stored/d. Thus, the addition of excess carbohydrate energy to a mixed diet so that total energy intake exceeded total energy expenditure (TEE) increased body fat stores, but not by conversion of the carbohydrate to fat.
Instead, the oxidation of dietary fat was suppressed and fat storage thereby increased.
Several points regarding the experimental design of McDevitt et al should be noted. First, the overfeeding protocol provided less total carbohydrate energy than daily TEE. It was therefore energetically possible to substitute carbohydrate for other fuels without changing TEE or breaking any laws of thermodynamics. The few exceptions to the rule that de novo lipogenesis is quantitatively minor have been when carbohydrate energy intake massively exceeds TEE, eg, the Guru Walla overfeeding tradition in Cameroon, wherein adolescent boys ingest > 29.3 MJ (7000 kcal) carbohydrate/d and gain 12 kg body fat over 10 wk while eating only 4 kg fat (5). Thus, de novo lipogenesis does become a quantitatively major pathway when carbohydrate energy intake exceeds TEE, but this circumstance is unusual in daily life.
Second, the period of overfeeding used by McDevitt et al (4) was relatively brief and included substantial dietary fat. Total body stores or proportions of different fatty acids would not have been altered by the 4-d protocol. If fatty acids themselves inhibit de novo lipogenesis, we cannot extrapolate the results to longer periods of surplus-carbohydrate, low-fat diets.
Third, the authors measured only hepatic, not adipose, de novo lipogenesis. Indeed, there is an element of tautology in the authors' argument that hepatic de novo lipogenesis is not quantitatively significant. McDevitt et al assumed a fixed VLDL-triacylglycerol production rate (30 g/d, or 300 mg · kg Ϫ1 · d Ϫ1 ) on the basis of values published in the literature. Even if de novo lipogenesis were 100%, the maximum quantitative contribution would be 30 g/d (compared with a carbohydrate intake of 350 g/d). It would have been preferable to measure VLDL-triacylglycerol production rates directly under the conditions of overfeeding to exclude the possibility of VLDL-triacylglycerol production rates of 100 g/d, for example.
Some experimental evidence for a potential role of adipose de novo lipogenesis has emerged. Aarsland et al (6) administered glucose to human subjects at rates greatly above TEE. After 4-7 d of overfeeding, hepatic de novo lipogenesis (measured isotopically) was stimulated 10-fold above baseline values but remained < 3% of whole-body net de novo lipogenesis according to indirect calorimetry. These authors concluded that adipose de novo lipogenesis must be occurring. Using very-long-term labeling protocols with 2 The model of the human macronutrient energy economy that emerges from the study of McDevitt et al is consistent with previous work (2, 3, 8, 9) . In the hierarchy of fuels, dietary carbohydrate appears to have a higher priority for oxidation than does dietary fat; when both are present, carbohydrate is chosen. The 2 major macronutrient energy sources (carbohydrates and fats) are not, however, interconvertible energy currencies. Fat cannot be converted to carbohydrate in animals because animals lack the enzymes of the glyoxylate pathway, and carbohydrate is not converted to fat because of a functional block of uncertain cause.
What are the implications of this model? Some conclusions should not be drawn. First, these results do not mean that extra carbohydrate energy represents "free" energy in terms of body fatness. By sparing fat in the body's fuel mixture, surplus carbohydrate energy will make people fatter, even though it is not directly converted to fat. The absence of significant de novo lipogenesis is bad news for high-carbohydrate dieters for another reason, in that the high thermogenic cost of de novo lipogenesis cannot be invoked as an energy-dissipating feature of such diets. Second, the effects of carbohydrate-rich diets on macronutrient balances should not be confused with their potential effect on plasma lipids and atherogenesis. High-carbohydrate euenergetic or hyperenergetic diets consistently induce hypertriglyceridemia, the public health consequences of which remain controversial (10) .
The implications of not having a single interconvertible energy currency, but instead having 2 independent, although interacting, macronutrient economies (8), remain intriguing and incompletely explored. Does the rule that carbohydrate availability to tissues controls whole-body fuel selection also apply to endogenous glucose production by the liver (9)? It might then be concluded that hepatic metabolism and hepatic genes are more likely to contribute to obesity through effects on glucose production than through effects on fat synthesis (11) . Also, are there regulatory, as opposed to quantitative, functions of the de novo lipogenesis pathway? Certainly, malonyl-CoA, the first committed metabolite in the de novo lipogenesis pathway, has several known regulatory actions. In addition to well-established antiketogenic actions in liver, malonyl-CoA concentrations are believed to influence fuel selection in muscle, fuel sensing and insulin secretion in the pancreatic ␤ cell, and perhaps fuel sensing and appetite regulation by the brain (12) . The fate of tissue malonyl-CoA generated for regulatory functions is a related, unanswered question (eg, is disposal of regulatory malonyl-CoA an unrecognized function of the de novo lipogenesis pathway?).
Finally, what is the role of de novo lipogenesis in human disease? Recent studies (13) have identified different insulin signaling pathways for de novo lipogenesis and cholesterol synthesis, on the one hand, and carbohydrate metabolism, on the other, as well as co-induction of de novo lipogenesis with cholesterogenesis by overexpression of the sterol response element binding protein. Thus, is de novo lipogenesis involved in the pathogenesis of insulin resistance or hypercholesterolemic syndromes? Or does de novo lipogenesis influence intracellular signaling pathways involving myristoylation, palmitoylation, or membrane fatty acids? These questions and more arise from the observation that de novo lipogenesis is the pathway of last resort and that, at least regarding converting carbohydrates to fats, humans are neither bees nor pigs.
